Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.

被引：4
|
作者：
Loibl, Sibylle
Majewski, Ian
Guarneri, Valentina
Nekljudova, Valentina
Holmes, Eileen McCormick
Bria, Emilio
Denkert, Carsten
Eidtmann, Holger
Sotiriou, Christos
Loi, Sherene
Andre, Fabrice
Untch, Michael
Conte, Pier Franco
Piccart-Gebhart, Martine J.
Von Minckwitz, Gunter
Baselga, Jose
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Univ Padua, IRCCS, Ist Oncol Veneto, Padua, Italy
[4] Frontier Sci Scotland, Kingussie, Inverness, Scotland
[5] Univ Verona, I-37100 Verona, Italy
[6] Charite, Inst Pathol, D-13353 Berlin, Germany
[7] Univ Kiel, Kiel, Germany
[8] Inst Jules Bordet, B-1000 Brussels, Belgium
[9] Peter MacCallum Canc Ctr, East Melbourne, Australia
[10] Inst Gustave Roussy, Villejuif, France
[11] Helios Klinikum Berlin Buch, Berlin, Germany
[12] IOV IRCCS, Inst Oncol Veneto, Padua, MO, Italy
[13] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis
    Ezzeldin M. Ibrahim
    Ghieth A. Kazkaz
    Mubarak M. Al-Mansour
    Meteb E. Al-Foheidi
    Breast Cancer Research and Treatment, 2015, 152 : 463 - 476
  • [42] Tumor mutation burden and PIK3CA mutations are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment.
    Shi, Qiyun
    Xuhong, Juncheng
    Ge, Jia
    Liu, Feng
    Lan, Yang
    Zhang, Yi
    Luo, Tao
    Bian, Xiuwu
    Qi, Xiaowei
    Jiang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] PIK3CA Mutation Assessment in HR+/HER2-Metastatic Breast Cancer: Overview for Oncology Clinical Practice
    Criscitiello, Carmen
    Marra, Antonio
    Curigliano, Giuseppe
    JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (01): : 42 - 54
  • [44] HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
    Schettini, Francesco
    Pascual, Tomas
    Conte, Benedetta
    Chic, Nuria
    Braso-Maristany, Fara
    Galvan, Patricia
    Martinez, Olga
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Fernandez-Martinez, Aranzazu
    Rognoni, Carla
    Griguolo, Gaia
    Guarneri, Valentina
    Conte, Pier Franco
    Locci, Mariavittoria
    Brase, Jan C.
    Gonzalez-Farre, Blanca
    Villagrasa, Patricia
    De Placido, Sabino
    Schiff, Rachel
    Veeraraghavan, Jamunarani
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Pernas, Sonia
    Perou, Charles M.
    Carey, Lisa A.
    Prat, Aleix
    CANCER TREATMENT REVIEWS, 2020, 84
  • [45] Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy
    Fontana, Andrea
    Allegrini, Giacomo
    al Zoubi, Mazhar
    Collecchi, Paola
    Mazzanti, Chiara
    Stasi, Irene
    Lucchesi, Sara
    Bona, Eleonora
    Ferrarini, Ilaria
    Salvadori, Barbara
    Arrighi, Giada
    Marcucci, Lorenzo
    Filidei, Mario
    Orlandini, Cinzia
    Falcone, Alfredo
    Bevilacqua, Generoso
    Zavaglia, Katia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] IMPACT OF PIK3CA MUTATIONS AND P95HER2 EXPRESSION ON THE OUTCOME OF HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH A TRASTUZUMAB-BASED THERAPY
    Stasi, I.
    Fontana, A.
    Allegrini, G.
    Mazzanti, C.
    Lucchesi, S.
    Bona, E.
    Ferrarini, I.
    Salvadori, B.
    Falcone, A.
    Zavaglia, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [47] Quantitative HER3 protein expression and PIK3CA mutation status in matched samples from primary and metastatic breast cancer tissues and correlation with time to recurrence
    Sperinde, J.
    Lara, J.
    Michaelson, R.
    Sun, X.
    Conte, P.
    Guarneri, V.
    Barbieri, E.
    Ali, S.
    Leitzel, K.
    Weidler, J.
    Lie, Y.
    Cook, J.
    Haddad, M.
    Paquet, A.
    Winslow, J.
    Howitt, J.
    Hurley, L.
    Eisenberg, M.
    Petropoulos, C.
    Huang, W.
    Lipton, A.
    CANCER RESEARCH, 2012, 72
  • [48] Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis
    Shi, Qiyun
    Xuhong, Juncheng
    Tian, Hao
    Qu, Man
    Zhang, Yi
    Jiang, Jun
    Qi, Xiaowei
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
  • [49] CORRELATION BETWEEN CIRCULATING TUMOR CELLS (CTCS), PET/CT RESPONSE AND PATHOLOGICAL COMPLETE RESPONSE (PCR) IN PRIMARY HER2-POSITIVE (HER2+) BREAST CANCER PATIENTS: A SUB-STUDY FROM THE NEOALTTO TRIAL
    Azim, H. A., Jr.
    Rothe, F.
    Aura, C. M.
    Bavington, M.
    Maetens, M.
    Rouas, G.
    De Azambuja, E.
    Sotiriou, C.
    Di Cosimo, S.
    Ignatiadis, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 98
  • [50] Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
    Liao, Ning
    Wang, Yulei
    Li, Kai
    Chen, Bo
    Zhang, Guo-Chun
    Li, XueRui
    Guo, Liping
    Cao, Li
    Ren, Chong-Yang
    Wen, Ling-Zhu
    Jia, Minghan
    Li, Cheukfai
    Mok, Hsiaopei
    Chen, Xiaoqing
    Wei, Guangnan
    Lin, Jiali
    Hou, Ting
    Han Han-Zhang
    Zhang, Zhou
    Liu, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345